HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Viagra Connect hits UK shelves

This article was originally published in OTC Bulletin & The Rose Sheet

Executive Summary

Pfizer is preparing a wide-ranging consumer marketing campaign to support the launch of its Viagra Connect (50mg sildenafil) product in the UK, after the country’s first OTC medicine for erectile dysfunction hit the shelves yesterday.

You may also be interested in...



Pfizer Building Viagra As Pan-European Consumer Health Brand With Rx-To-OTC Switch In Norway

Pfizer has taken the first steps towards turning its Viagra erectile dysfunction treatment into a pan-European OTC brand by taking advantage of Norway's new "non-prescription medicines with guidance" category to secure the Rx-to-OTC switch of the product. Norway will be the second European market where Viagra is available OTC after the UK switched the drug in 2017.

Thinking About Switching? Dr Gauld On The Go-To Markets Today

In this first installment of an exclusive three-part series, global switch expert Dr Natalie Gauld speaks to HBW Insight about what makes a country an attractive environment for switching and highlights those markets leading the way today. 

China Approves World’s First Bispecific IO Drug Amid PD-1/L1 Glut

Akeso’s PD-1/CTLA-4-targeting therapy cadonilimab has been the front-runner in the bispecific antibody field in China, leading about 50 other similar agents under development by domestic pharma firms. With a new conditional approval, it has also gained a head start over home-grown PD-1/L1 antibody rivals in the cervical cancer space.

Topics

Latest News
UsernamePublicRestriction

Register

RS122113

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel